RMC No. 131-2024 updates the VAT-exempt medicine list for cancer, diabetes, and mental illness products, with effectivity tied to FDA publication.
Businesses selling, dispensing, importing, distributing, or accounting for qualified medicines must immediately check the latest FDA-published list of VAT-exempt medicines because the VAT exemption under the CREATE Act takes effect based on the FDA’s publication of the updated list. RMC No. 131-2024 matters now because it confirms updates affecting medicines for cancer, diabetes, and mental illness, and it alerts taxpayers that some cancer medicine entries were corrected or deleted.
What RMC No. 131-2024 Changed
RMC No. 131-2024 publishes the full text of the October 14, 2024 letter from the Food and Drug Administration of the Department of Health endorsing updates to the list of VAT-exempt products under Republic Act No. 10963, or the TRAIN Law, and Republic Act No. 11534, or the CREATE Act.
The key change is not a new VAT rate. The important change is the updating of the official list of VAT-exempt medicines. The circular identifies two principal updates: the inclusion of certain medicines for cancer, diabetes, and mental illness, and the correction and deletion of medicine for cancer.
For Philippine businesses, the practical consequence is direct: a medicine is not treated as VAT-exempt merely because it is generally connected with cancer, diabetes, or mental illness. Taxpayers must verify whether the specific product is included in the FDA-published list, whether the entry has been corrected, and whether a previous cancer medicine entry has been deleted.
Why the FDA Publication Date Matters for VAT Exemption
RMC No. 131-2024 reiterates the rule previously clarified in Q&A No. 1 of RMC No. 99-2021: the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act is the date of publication by the FDA of the updates to the list.
This timing rule is critical for accountants and tax managers because it determines when sales should be treated as VAT-exempt. A company should not simply apply VAT exemption retroactively or prospectively based on internal assumptions. The controlling date for the listed product is the date when the FDA publishes the update to the relevant list.
For businesses searching for RMC No. 131-2024 VAT-exempt medicines, FDA VAT-exempt medicine list Philippines, VAT exemption cancer medicines CREATE Act, VAT-exempt diabetes medicines BIR, and VAT-exempt mental illness medicines Philippines, the central compliance point is that tax treatment must be tied to the updated FDA list and its publication date.
Who Is Affected by RMC No. 131-2024
The taxpayers most affected are businesses involved in the sale, purchase, importation, distribution, or dispensing of medicines for cancer, diabetes, and mental illness. This includes pharmacies, drugstores, hospitals, clinics, medicine distributors, importers, manufacturers, wholesalers, and other VAT-registered taxpayers handling covered medicines.
Corporate accountants and CFOs are also directly affected because VAT treatment impacts invoicing, sales reporting, VAT returns, inventory records, pricing, and customer billing. If a product is newly included in the FDA-published VAT-exempt list, the accounting system must reflect that treatment from the proper effectivity date. If a cancer medicine entry has been corrected or deleted, the business must ensure that the product is not wrongly sold, recorded, or reported as VAT-exempt.
In-house counsel and tax practitioners should also review contracts, price lists, purchase orders, and supply arrangements involving medicines. Where prices are expressed as VAT-inclusive or VAT-exclusive, the change in VAT classification may affect billing assumptions and commercial documentation.
Key Compliance Requirements and Deadlines
RMC No. 131-2024 is dated 2024 and bears a release stamp of December 3, 2024. The underlying FDA endorsement letter is dated October 14, 2024. However, the circular does not create a single universal deadline for all taxpayers to comply. Instead, the controlling compliance trigger is the FDA publication of the updates to the list of VAT-exempt medicines and medical devices.
Taxpayers should therefore identify the exact FDA publication date applicable to the updated list and apply the VAT exemption only in accordance with that publication. The circular does not provide a product-by-product table in its main text, but it expressly states that the updates concern the inclusion of certain medicines for cancer, diabetes, and mental illness, and the correction and deletion of medicine for cancer.
The immediate compliance requirement is verification. Businesses should not rely on generic descriptions such as cancer drug, diabetes medicine, or mental health medicine. They should match the specific medicine against the current FDA-published VAT-exempt list and document the basis for VAT-exempt treatment.
Penalties and Tax Risks for Non-Compliance
RMC No. 131-2024 does not state a new special penalty for non-compliance. It is a circular for information and guidance, publishing the FDA endorsement and reminding concerned taxpayers of the effectivity rule for VAT exemption under the CREATE Act.
Even without a special penalty in the circular, incorrect VAT treatment can still create audit exposure under existing tax rules. If a business treats a non-listed or deleted medicine as VAT-exempt, the BIR may question the understatement or non-imposition of VAT. If a business continues to impose VAT on a medicine that is already covered by the FDA-published VAT-exempt list, it may face customer disputes, pricing issues, and accounting corrections.
The risk is especially high for businesses with large inventories, multiple branches, point-of-sale systems, or mixed sales of VATable and VAT-exempt products. A single classification error can be replicated across many transactions if the product master file, invoicing system, or sales tax code is not updated.
Practical Steps for Businesses
First, obtain and review the latest FDA-published list of VAT-exempt medicines and medical devices relevant to cancer, diabetes, and mental illness. The business should confirm whether each product it sells or purchases is included, corrected, or deleted.
Second, update product master files, accounting software, POS systems, invoice templates, and tax codes. The VAT classification should match the FDA-published list and should be effective only from the proper publication date.
Third, review transactions occurring around the FDA publication date. This is important because the CREATE Act VAT exemption, as clarified by RMC No. 99-2021 and reiterated in RMC No. 131-2024, becomes effective on the date of FDA publication of the updates.
Fourth, document the basis for VAT-exempt treatment. The company’s tax file should show the FDA list relied upon, the relevant publication date, the product classification, and the internal approval or system update implementing the change.
Fifth, coordinate between tax, finance, pharmacy operations, procurement, and IT. VAT classification is not only a legal issue. It is also a systems issue. A taxpayer may know the correct rule but still commit errors if the product database or POS configuration is not updated.
How Ablola, Saribong & Gueco Can Help
RMC No. 131-2024 is a reminder that VAT exemption for medicines is highly technical and product-specific. Businesses dealing with medicines for cancer, diabetes, and mental illness should not wait for a BIR audit before reconciling their VAT treatment with the latest FDA-published list.
Ablola, Saribong & Gueco assists businesses, CFOs, accountants, healthcare companies, pharmacies, distributors, importers, and in-house legal teams in reviewing VAT classifications, BIR issuances, invoice practices, and tax compliance systems. For assistance with VAT-exempt medicines, CREATE Act compliance, BIR audits, or tax advisory work, visit MakatiLawFirm.com.